Abstract

Burimamide and metiamide which have been described previously (Black, Duncan, Durant, Ganellin & Parsons, 1972; Black, Duncan, Emmett, Ganellin, Hesselbo, Parsons & Wyllie, 1973) are histamine H2-receptor antagonists. This communication describes some aspects of the pharmacology of cimetidine (N-cyano-N′-methyl-N″[2-(5- methyl-4-imidazolyl-methylthio)ethyl] guanidine; SK&F 92334), a new H2-receptor antagonist. In vitro the compound antagonizes the actions of histamine on isolated guinea-pig atrium and isolated electrically-stimulated rat uterus with KB values of 7.9 × 10−7m and 8.1 × 10−7m respectively, corresponding to pA2 values of 6.1 on each tissue. At very high concentrations cimetidine antagonizes the actions of isoprenaline on atrium and uterus and the actions of histamine and carbachol on isolated guinea-pig ileum but the results are not consistent with competitive antagonism at β-adrenoceptors, histamine H1-receptors or muscarinic receptors. The effects of cimetidine on gastric acid secretion have been studied in a number of preparations. The results are summarized in Table 1. In all preparations cimetidine was approximately equiactive in inhibiting histamine and pentagastrin-stimulated acid secretion but less effective in inhibiting carbachol-stimulated secretion. Basal secretion was also inhibited. In Heidenhain pouch dogs the blood levels to give 50% inhibition of maximally-stimulated gastric secretion (EC50) were approximately 1–2 µm and the half-life of the compound about one hour. Table 1 The effects of cimetidine on gastric acid secretion In male human volunteers cimetidine given intravenously has been shown to inhibit histamineor pentagastrin-stimulated gastric secretion with an EC50 of about 2.5 μm and a half-life of about two hours. In chronic toxicity studies metiamide has been shown at high doses to produce kidney damage and agranulocytosis in some dogs (Brimblecombe, Duncan & Walker, 1973). In tests so far carried out cimetidine at equivalent doses has not shown similar toxicity.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.